Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Objective To evaluate the accumulated information from genetic association studies
investigating the impact of variants of the cytochrome P450 (CYP) 2C19 genotype on the …

ANGIOLILLO DJ et al. large-and medium-sized arteries triggers platelet activation, leading to
thrombotic occlusion of the blood vessels. 1 The thrombi block blood flow and oxygen …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

Background Previous studies have investigated the relationship between CYP2C19
polymorphism and clinical prognosis in coronary artery disease patients treated with …

Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been
hypothesized to be associated with lesser degrees of platelet inhibition and increased risk …